Skip to content

Lavender During Intrauterine Insemination

Lavender Aromatherapy vs Placebo to Decrease Anxiety and Pain During Intrauterine Insemination (IUI).

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03461055
Enrollment
62
Registered
2018-03-09
Start date
2017-05-24
Completion date
2018-04-16
Last updated
2018-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female, Anxiety

Brief summary

The Researchers hope to learn if by using lavender aromatherapy during an intrauterine insemination patients have decreased anxiety and pain at the time of the procedure.

Detailed description

Infertility patients have a high level of anxiety before and during infertility treatments due to anticipated discomfort of a procedure and anticipation of a long awaited pregnancy. Aromatherapy with lavender, an essential oil, has been shown to be effective in reducing anxiety and pain in a variety of procedures such as Botox injections, cesarean delivery and intrauterine device placement.

Interventions

Lavender aromatherapy

OTHERWater

Water

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Women undergoing intrauterine insemination * English speaking

Exclusion criteria

* Allergy to lavender oil or its components * Currently using aromatherapy * Contraindication to intrauterine insemination * Contraindication to pregnancy

Design outcomes

Primary

MeasureTime frameDescription
AnxietyDuring intrauterine insemination procedureAnxiety level using a standard visual analog scale. Scale is from 0-100 mm. 0 is absent anxiety. 100 mm is maximal anxiety.

Secondary

MeasureTime frameDescription
PainDuring intrauterine insemination procedurePain score using Wong-Baker pain scale of 0-10. 0 being absent pain and 10 being maximal pain.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026